Analysts See $-0.67 EPS for Karyopharm Therapeutics Inc. (KPTI); TripAdvisor, Inc. (TRIP) Had 0 Bulls

April 17, 2018 - By Richard Conner

TripAdvisor, Inc. (NASDAQ:TRIP) Logo

Among 33 analysts covering TripAdvisor LLC (NASDAQ:TRIP), 0 have Buy rating, 7 Sell and 26 Hold. Therefore 0 are positive. TripAdvisor LLC had 87 analyst reports since July 21, 2015 according to SRatingsIntel. SunTrust maintained the shares of TRIP in report on Thursday, February 15 with “Hold” rating. The firm has “Neutral” rating given on Friday, November 6 by Guggenheim. Macquarie Research downgraded the stock to “Neutral” rating in Tuesday, October 27 report. The firm earned “Sector Perform” rating on Friday, February 12 by RBC Capital Markets. Deutsche Bank downgraded the stock to “Hold” rating in Friday, August 5 report. On Tuesday, January 10 the stock rating was initiated by Citigroup with “Neutral”. Stifel Nicolaus maintained TripAdvisor, Inc. (NASDAQ:TRIP) rating on Wednesday, August 9. Stifel Nicolaus has “Hold” rating and $4000 target. The stock of TripAdvisor, Inc. (NASDAQ:TRIP) has “Buy” rating given on Friday, July 24 by Deutsche Bank. UBS maintained TripAdvisor, Inc. (NASDAQ:TRIP) rating on Friday, November 6. UBS has “Neutral” rating and $76 target. On Thursday, December 10 the stock rating was maintained by Piper Jaffray with “Overweight”. See TripAdvisor, Inc. (NASDAQ:TRIP) latest ratings:

04/04/2018 Broker: Wedbush Rating: Neutral New Target: $42 Initiates Coverage On
04/04/2018 Broker: DA Davidson Rating: Neutral New Target: $46 Initiates Coverage On
22/03/2018 Broker: Mizuho Rating: Neutral New Target: $40 Initiates Coverage On
16/02/2018 Broker: Barclays Capital Rating: Hold New Target: $41.0 Maintain
16/02/2018 Broker: Susquehanna Rating: Hold New Target: $45.0 Maintain
15/02/2018 Broker: SunTrust Rating: Hold New Target: $40.0 Maintain
15/02/2018 Broker: Stifel Nicolaus Rating: Hold New Target: $40.0 Maintain
15/02/2018 Broker: RBC Capital Markets Rating: Hold New Target: $45.0 Maintain
05/02/2018 Broker: SunTrust Rating: Hold New Target: $37.0 Maintain
27/11/2017 Broker: Cowen & Co Old Rating: Market Perform New Rating: Market Perform Old Target: $30 New Target: $40 Maintain

Analysts expect Karyopharm Therapeutics Inc. (NASDAQ:KPTI) to report $-0.67 EPS on May, 3.They anticipate $0.04 EPS change or 5.63% from last quarter’s $-0.71 EPS. After having $-0.80 EPS previously, Karyopharm Therapeutics Inc.’s analysts see -16.25% EPS growth. The stock increased 3.27% or $0.46 during the last trading session, reaching $14.51. About 96,837 shares traded. Karyopharm Therapeutics Inc. (NASDAQ:KPTI) has risen 23.92% since April 17, 2017 and is uptrending. It has outperformed by 12.37% the S&P500.

Since December 11, 2017, it had 0 buys, and 23 selling transactions for $2.49 million activity. $91,553 worth of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) was sold by Kauffman Michael on Monday, December 18. The insider Shacham Sharon sold $91,553. Shares for $37,527 were sold by Primiano Christopher Brett on Thursday, February 15. The insider Mirza Mansoor Raza sold $40,000.

Karyopharm Therapeutics Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. The company has market cap of $720.46 million. The Company’s lead drug candidate is Selinexor, which is in Phase IIb clinical trial for patients with heavily pretreated multiple myeloma; Phase Ib/II clinical study in combination with backbone treatments for relapsed/refractory multiple myeloma; Phase II/III clinical trial for patients with relapsed and/or refractory multiple myeloma; Phase II clinical study to treat acute myeloid leukemia; Phase IIb clinical trial for patients with diffuse large B-cell lymphoma; and Phase II/III clinical trial to treat liposarcoma. It currently has negative earnings. The firm is also developing KPT-8602 that is in Phase I/II study for patients with relapsed/refractory multiple myeloma; KPT-9274, which is in Phase I clinical trial for patients with advanced solid malignancies or non-Hodgkin's lymphoma; KPT-335, which is in Phase I clinical trial for the treatment of viral indications; and KPT-350 that is in preclinical stage to treat neurological disorders, and inflammatory and autoimmune diseases.

Investors sentiment decreased to 1.56 in 2017 Q4. Its down 0.94, from 2.5 in 2017Q3. It is negative, as 4 investors sold Karyopharm Therapeutics Inc. shares while 21 reduced holdings. 11 funds opened positions while 28 raised stakes. 30.26 million shares or 8.41% more from 27.91 million shares in 2017Q3 were reported. Moreover, Goldman Sachs Gp has 0% invested in Karyopharm Therapeutics Inc. (NASDAQ:KPTI) for 78,107 shares. 69,928 are held by Morgan Stanley. Northern Tru invested in 385,717 shares or 0% of the stock. Jacobs Levy Equity Mngmt has 0.01% invested in Karyopharm Therapeutics Inc. (NASDAQ:KPTI) for 53,200 shares. Point72 Asia (Hong Kong) Limited holds 334 shares. Raymond James & Assoc invested in 19,734 shares. State Street Corp has 589,786 shares for 0% of their portfolio. Art Advsrs Ltd Liability Co invested 0.01% of its portfolio in Karyopharm Therapeutics Inc. (NASDAQ:KPTI). Bnp Paribas Arbitrage Sa has 0% invested in Karyopharm Therapeutics Inc. (NASDAQ:KPTI) for 7,123 shares. 54,308 are held by Citadel Advsrs Llc. Ameritas Invest Prtn Inc accumulated 0% or 2,967 shares. Panagora Asset Mngmt invested in 146,918 shares or 0.01% of the stock. Prudential Fincl Incorporated has invested 0% in Karyopharm Therapeutics Inc. (NASDAQ:KPTI). Teacher Retirement Sys Of Texas accumulated 12,030 shares or 0% of the stock. Macquarie Group Incorporated Ltd holds 900 shares.

Among 13 analysts covering Karyopharm Therapeutics Inc. (NASDAQ:KPTI), 12 have Buy rating, 1 Sell and 0 Hold. Therefore 92% are positive. Karyopharm Therapeutics Inc. had 34 analyst reports since August 11, 2015 according to SRatingsIntel. The firm earned “Outperform” rating on Tuesday, June 28 by Robert W. Baird. The firm earned “Underperform” rating on Tuesday, March 15 by Bank of America. The firm has “Buy” rating by RBC Capital Markets given on Friday, March 2. On Tuesday, August 30 the stock rating was upgraded by Jefferies to “Buy”. On Tuesday, August 11 the stock rating was maintained by Leerink Swann with “Outperform”. On Wednesday, January 6 the stock rating was downgraded by Jefferies to “Hold”. As per Tuesday, March 15, the company rating was maintained by Jefferies. The stock has “Overweight” rating by JP Morgan on Tuesday, April 10. The firm earned “Buy” rating on Monday, September 11 by Jefferies. The firm has “Buy” rating given on Wednesday, August 12 by MLV.

Investors sentiment increased to 1.24 in 2017 Q4. Its up 0.30, from 0.94 in 2017Q3. It is positive, as 58 investors sold TripAdvisor, Inc. shares while 73 reduced holdings. 47 funds opened positions while 116 raised stakes. 115.06 million shares or 4.24% less from 120.15 million shares in 2017Q3 were reported. Sun Life Finance reported 0% in TripAdvisor, Inc. (NASDAQ:TRIP). 22,274 are held by Hartford Inv Mngmt. First Mercantile Com invested in 0.17% or 25,122 shares. Malaga Cove Cap Limited invested 1.26% in TripAdvisor, Inc. (NASDAQ:TRIP). Dimensional Fund Advisors Lp, a Texas-based fund reported 521,270 shares. Benjamin F Edwards & owns 40 shares or 0% of their US portfolio. Gemmer Asset owns 0% invested in TripAdvisor, Inc. (NASDAQ:TRIP) for 227 shares. New York-based Bnp Paribas Arbitrage Sa has invested 0.01% in TripAdvisor, Inc. (NASDAQ:TRIP). Lpl Finance Ltd Co invested in 0% or 27,154 shares. D E Shaw & has 600,802 shares for 0.03% of their portfolio. Aperio Grp Lc invested 0.01% in TripAdvisor, Inc. (NASDAQ:TRIP). Comerica Fincl Bank holds 0.01% of its portfolio in TripAdvisor, Inc. (NASDAQ:TRIP) for 31,441 shares. Ariel Lc reported 0.03% stake. Zurcher Kantonalbank (Zurich Cantonalbank) accumulated 37,673 shares or 0.01% of the stock. Texas-based Teacher Retirement Sys Of Texas has invested 0.01% in TripAdvisor, Inc. (NASDAQ:TRIP).

TripAdvisor, Inc. operates as an online travel company. The company has market cap of $5.84 billion. The firm operates through two divisions, Hotel and Non-Hotel. It currently has negative earnings. The Company’s travel platform aggregates reviews and opinions of members about destinations, accommodations, activities and attractions, and restaurants, which enables users to research and plan their travel experiences, as well as book hotels, flights, cruises, vacation rentals, activities and attractions, and restaurant reservations.

Since December 18, 2017, it had 0 insider buys, and 3 insider sales for $1.51 million activity. TEUNISSEN ERNST 02494 also sold $378,280 worth of TripAdvisor, Inc. (NASDAQ:TRIP) on Tuesday, February 6. Nishar Dipchand sold $11,937 worth of TripAdvisor, Inc. (NASDAQ:TRIP) on Monday, December 18. Halpin Dermot sold 26,313 shares worth $1.12 million.

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By1 Richard Conner

Automatic Stock Updates

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: